FY2026 EPS Estimates for AXSM Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings estimate for Axsome Therapeutics to ($2.27) per share, improving from the previous estimate of ($2.73), while maintaining a "Strong-Buy" rating on the stock.
• Axsome Therapeutics reported quarterly earnings of ($0.92) per share, surpassing the consensus estimate by $0.08 and generating $150.04 million in revenue.
• Institutional investors now own 81.49% of Axsome’s stock, indicating strong support from hedge funds and large investors following significant purchasing activity in recent quarters.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for Axsome Therapeutics in a research report issued on Wednesday, August 6th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($2.27) per share for the year, up from their prior estimate of ($2.73). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. The firm had revenue of $150.04 million for the quarter, compared to analyst estimates of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.

Other equities research analysts have also issued research reports about the stock. Bank of America increased their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a "buy" rating in a report on Tuesday. Wells Fargo & Company reissued an "overweight" rating and set a $165.00 price objective (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. Royal Bank Of Canada increased their price objective on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an "outperform" rating in a report on Tuesday. Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $150.00 price objective on shares of Axsome Therapeutics in a report on Monday. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Axsome Therapeutics currently has a consensus rating of "Buy" and an average target price of $178.00.

Axsome Therapeutics Price Performance

Shares of AXSM traded down $0.87 during trading hours on Friday, hitting $103.45. The stock had a trading volume of 49,704 shares, compared to its average volume of 786,610. The company's fifty day moving average is $105.86 and its two-hundred day moving average is $110.73. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.96. Axsome Therapeutics has a 52 week low of $75.56 and a 52 week high of $139.13. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of -20.46 and a beta of 0.51.

Insider Activity at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 25,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $110.44, for a total value of $2,761,000.00. Following the sale, the chief operating officer directly owned 5,783 shares in the company, valued at $638,674.52. This trade represents a 81.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark Coleman sold 3,750 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the completion of the sale, the director owned 50,387 shares in the company, valued at $5,314,316.89. This represents a 6.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 93,437 shares of company stock worth $9,834,215 in the last ninety days. Company insiders own 22.30% of the company's stock.

Institutional Trading of Axsome Therapeutics

Hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. grew its stake in shares of Axsome Therapeutics by 16,852.7% during the 1st quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company's stock worth $73,176,000 after acquiring an additional 623,717 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at $39,767,000. Lazard Asset Management LLC grew its stake in shares of Axsome Therapeutics by 525.7% in the fourth quarter. Lazard Asset Management LLC now owns 537,669 shares of the company's stock valued at $45,492,000 after buying an additional 451,737 shares in the last quarter. Nuveen LLC bought a new position in shares of Axsome Therapeutics in the first quarter valued at $48,185,000. Finally, 1832 Asset Management L.P. bought a new position in shares of Axsome Therapeutics in the first quarter valued at $42,360,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.